Muscle Spasticity Market to Grow with a CAGR of 8.27% through 2028
Rising incidence of neurological disorders are expected
to drive the Global Muscle Spasticity Market growth in the forecast period,
2024-2028.
According to TechSci Research report, “Muscle
Spasticity Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Muscle Spasticity Market
stood at USD 3.86 billion in 2022 and is anticipated to grow with a CAGR of 4.93%
in the forecast period, 2024-2028. One of the primary drivers fueling the growth of the
muscle spasticity market is the escalating prevalence of neurological disorders
worldwide. Conditions such as multiple sclerosis, which affects millions of
individuals globally, are associated with muscle spasticity. As the incidence
of these neurological disorders continues to rise, so does the demand for
effective treatments to manage the associated muscle spasticity symptoms.
Pharmaceutical companies have responded to this need by developing a range of
medications tailored to alleviate muscle stiffness and discomfort. Pharmaceutical
interventions form a significant segment of the muscle spasticity market. Over
the years, there has been a notable surge in the development and
commercialization of muscle relaxants and anti-spasticity drugs. These
medications work to alleviate muscle spasticity symptoms, providing patients
with much-needed relief and improved quality of life. As research into
neurological conditions deepens and our understanding of the underlying
mechanisms improves, we can anticipate the development of even more effective
pharmaceutical therapies. Beyond pharmaceutical solutions, non-pharmacological
approaches have gained traction in the management of muscle spasticity. These
include physical therapy, occupational therapy, and orthopedic interventions,
among others. Awareness about the effectiveness of these alternative treatment
modalities has been on the rise, with patients and healthcare providers
increasingly recognizing their value in improving patient outcomes. This shift
towards holistic and multidisciplinary approaches to muscle spasticity
treatment is contributing to the market's growth.
The muscle spasticity market has benefited
significantly from technological advancements in medical devices and treatment
options. Innovative approaches, such as implantable neurostimulation devices
and botulinum toxin injections, have revolutionized the management of muscle
spasticity. These technologies offer targeted and minimally invasive solutions,
greatly enhancing patient comfort and outcomes. The continual evolution of
these technologies ensures that the muscle spasticity market remains dynamic
and adaptable to changing patient needs. Aging populations worldwide are also
contributing to the growth of the muscle spasticity market. Muscle spasticity
is not limited to specific age groups, but it is often associated with
conditions that become more prevalent with age, such as multiple sclerosis or
stroke. As the global population ages, the demand for treatments for muscle
spasticity is likely to increase, creating a significant market driver. Improvements
in healthcare infrastructure and access to medical services are critical
drivers of market growth. Access to specialized care and treatment options for
muscle spasticity is becoming more widespread, even in remote and underserved
regions. This improved accessibility ensures that a broader population can
benefit from effective interventions, further boosting market demand.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Muscle Spasticity Market.”
The Global Muscle Spasticity Market is segmented into drug
type, route of administration, distribution channel, regional distribution, and
company.
Based on type, the Global Muscle Spasticity Market is
segmented into Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others. Based on the
drug Type, the Botulinum Toxin segment emerged as the dominant player in the
global market for Global Muscle Spasticity Market in 2022. This dominance can
be attributed to several key factors including proven efficacy, Minimally
invasive and targeted treatment of botulin toxin. Botulinum toxin
injections have demonstrated their effectiveness in managing muscle spasticity.
These injections work by blocking the release of acetylcholine at nerve-muscle
junctions, leading to muscle relaxation. This mechanism of action has been
well-established through clinical trials and real-world patient outcomes,
making botulinum toxin a trusted and reliable treatment option. Botulinum toxin
injections are minimally invasive and typically performed in an outpatient
setting. This non-surgical approach appeals to both patients and healthcare
providers, as it avoids the risks and recovery time associated with invasive
procedures. Botulinum toxin injections can be precisely targeted to specific
muscles or muscle groups affected by spasticity. This level of precision allows
for tailored treatment plans, minimizing side effects and maximizing the
therapeutic benefits for patients.
Based on route of administration, the Global Muscle
Spasticity Market is segmented into Oral, Intramuscular, Others.Based on the Route of
Administration, the Oral segment emerged as the dominant player in the global
market for Global Muscle Spasticity Market in 2022 Oral medications are easy to
administer and do not require specialized training or equipment. Patients can
take their medication at home without the need for frequent clinic visits,
making it a convenient option for long-term management. Oral medications are
generally well-tolerated by patients, and compliance tends to be high. This is
important for chronic conditions like muscle spasticity, where adherence to
treatment regimens is crucial for maintaining symptom control. Oral medications
for muscle spasticity, such as baclofen and tizanidine, are readily available
and have been used for many years. They have a well-established safety profile,
which contributes to their popularity. Dosing of oral medications can be
adjusted to suit individual patient needs, allowing healthcare providers to
fine-tune treatment plans based on the severity of spasticity and the patient's
response.
North America emerged as the dominant player in the
global Muscle Spasticity Market in
2022, holding the largest market share. North America benefits from a
well-established healthcare infrastructure and a high level of awareness
regarding neurological disorders and muscle spasticity. This translates into
early diagnosis and effective treatment, contributing to the region's
leadership in market share. Secondly, the region is a hub for pharmaceutical
innovation and medical research. It boasts a significant number of
pharmaceutical companies, research institutions, and healthcare facilities that
continually advance the development of new treatments and therapies for muscle
spasticity.
Major companies operating in Global Muscle
Spasticity Market are:
- Ipsen Pharma
- Allergan
- Acorda Therapeutics, Inc.
- Merz Pharma
- Novartis AG
- Beximco Pharmaceuticals Ltd.
- Zydus Cadila
- Porex Corporation
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global
Muscle Spasticity Market is poised for significant growth in the coming years,
primarily driven by several key factors. Firstly, the increasing prevalence of
neurological disorders, such as multiple sclerosis, cerebral palsy, and stroke,
is contributing to a higher incidence of muscle spasticity worldwide. As the
global population ages and lifestyles evolve, the demand for effective muscle
spasticity management is on the rise. Besides advancements in therapeutic
options are expanding treatment horizons for patients. Innovative approaches,
including botulinum toxin injections, minimally invasive procedures, and
neuromuscular electrical stimulation devices, offer more effective and patient-friendly
solutions. These developments not only improve patient outcomes but also
attract a broader patient base seeking relief from muscle spasticity.
Additionally, heightened awareness and education campaigns have led to earlier
diagnosis and intervention. As patients and healthcare providers become more
informed about muscle spasticity, the trend toward timely treatment continues
to grow.” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Muscle Spasticity Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug
Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others), By Route
of Administration (Oral, Intramuscular, Others), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Competition”, has evaluated
the future growth potential of Global Muscle Spasticity Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Muscle Spasticity Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com